2 research outputs found
PR3-ANCAs Detected by Third-Generation ELISA Predicts Severe Disease and Poor Survival in Primary Sclerosing Cholangitis
A highly sensitive detection of anti-neutrophil cytoplasmic antibodies to serine
proteinase-3 (PR3-ANCAs) aids in the serological diagnosis of autoimmune liver disorders and the
prediction of severity in primary sclerosing cholangitis (PSC). Here, we evaluate a novel thirdgeneration ELISA for the detection of PR3-ANCAs. In total, 309 patients with PSC, 51 with primary
biliary cholangitis (PBC), and 120 healthy blood donors (BD) were analyzed. For the survival
analysis in PSC, the outcome was defined as liver-transplantation-free survival during the followup. Positive PR3-ANCA levels were found in 74/309 (24.0%) of patients with PSC. No BDs and one
patient with PBC demonstrated PR3-ANCA positivity. PR3-ANCAs were revealed as independent
predictors for a poor PSC outcome (study endpoint: liver transplantation/death, log-rank test, p =
0.02). PR3-ANCA positivity, lower albumin levels, and higher bilirubin concentrations were
independent risks of a poor survival (Cox proportional-hazards regression analysis, p < 0.05). The
Mayo risk score for PSC was associated with PR3-ANCA positivity (p = 0.01) and the disease
severity assessed with a model of end-stage liver disease (MELD) and extended MELD-Na (p < 0.05).
PR3-ANCAs detected by a third-generation ELISA are diagnostic and prognostic markers for PSC.
Their wider use could help to identify patients who are at-risk of a more severe disease
PR3-ANCAs Detected by Third-Generation ELISA Predicts Severe Disease and Poor Survival in Primary Sclerosing Cholangitis
A highly sensitive detection of anti-neutrophil cytoplasmic antibodies to serine proteinase-3 (PR3-ANCAs) aids in the serological diagnosis of autoimmune liver disorders and the prediction of severity in primary sclerosing cholangitis (PSC). Here, we evaluate a novel third-generation ELISA for the detection of PR3-ANCAs. In total, 309 patients with PSC, 51 with primary biliary cholangitis (PBC), and 120 healthy blood donors (BD) were analyzed. For the survival analysis in PSC, the outcome was defined as liver-transplantation-free survival during the follow-up. Positive PR3-ANCA levels were found in 74/309 (24.0%) of patients with PSC. No BDs and one patient with PBC demonstrated PR3-ANCA positivity. PR3-ANCAs were revealed as independent predictors for a poor PSC outcome (study endpoint: liver transplantation/death, log-rank test, p = 0.02). PR3-ANCA positivity, lower albumin levels, and higher bilirubin concentrations were independent risks of a poor survival (Cox proportional-hazards regression analysis, p < 0.05). The Mayo risk score for PSC was associated with PR3-ANCA positivity (p = 0.01) and the disease severity assessed with a model of end-stage liver disease (MELD) and extended MELD-Na (p < 0.05). PR3-ANCAs detected by a third-generation ELISA are diagnostic and prognostic markers for PSC. Their wider use could help to identify patients who are at-risk of a more severe disease